Summary
Zoetis Inc. reported a solid first quarter for 2017, with total revenue increasing by 6% to $1.23 billion compared to the same period in 2016. This growth was primarily driven by new product launches and increased sales of key products like Apoquel®, contributing approximately 6% to revenue, alongside a 2% contribution from in-line products due to price increases. The company also saw positive operational revenue growth across both its U.S. and International segments, with companion animal products showing particular strength. Net income attributable to Zoetis Inc. rose by 17% to $238 million, or $0.48 per diluted share, up from $204 million, or $0.41 per diluted share, in the prior year. This improvement was significantly influenced by a lower effective tax rate in the current quarter, which decreased to 29.1% from 38.6% in Q1 2016, largely due to discrete tax benefits and a favorable shift in the jurisdictional mix of earnings. The company continued to execute on its operational efficiency initiatives, leading to a decrease in SG&A expenses and managing R&D expenses effectively while maintaining investment in innovation. Zoetis also demonstrated strong cash flow generation from operations.
Financial Highlights
53 data points| Revenue | $1.23B |
| Cost of Revenue | $443.00M |
| Gross Profit | $788.00M |
| SG&A Expenses | $309.00M |
| Operating Expenses | $895.00M |
| Interest Expense | $41.00M |
| Net Income | $239.00M |
| EPS (Basic) | $0.48 |
| EPS (Diluted) | $0.48 |
| Shares Outstanding (Basic) | 492.40M |
| Shares Outstanding (Diluted) | 495.30M |
Key Highlights
- 1Total revenue grew 6% to $1.23 billion in Q1 2017, driven by new product launches (e.g., Apoquel®, Simparica®, Cytopoint™) and in-line product performance.
- 2Net income attributable to Zoetis Inc. increased 17% to $238 million, resulting in diluted EPS of $0.48, up from $0.41 in Q1 2016.
- 3Effective tax rate improved significantly to 29.1% in Q1 2017 from 38.6% in Q1 2016, positively impacting net income.
- 4Selling, General & Administrative (SG&A) expenses decreased by 2% due to cost-reduction initiatives and lower costs related to becoming an independent public company.
- 5Research and Development (R&D) expenses remained flat, with increased variable spending on projects offset by reduced fixed expenses from efficiency initiatives.
- 6Net cash provided by operating activities was $119 million, a substantial increase from $51 million in the prior year's quarter, indicating strong operational cash generation.
- 7The company authorized an additional $1.5 billion share repurchase program in December 2016 and had approximately $1.4 billion remaining as of April 2, 2017.